Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 December;54(6) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 December;54(6):574-81

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  MONOCLONAL ANTIBODIES FOR DIAGNOSIS AND THERAP Y DECISION MAKING IN INFLAMMATION/INFECTION


The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 December;54(6):574-81

language: English

An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicine

Goldsmith S. J. 1, Signore A. 2

1 New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA;
2 Nuclear Meidicine Unit, Faculty of Medicine and Psychology, La Sapienza University, Rome, Italy


PDF  REPRINTS


Monoclonal antibodies, which include murine, chimeric, humanised and fully human antibodies, bind to their target receptors with high affinity and specificity. In the last two decades several different monoclonal antibodies have been approved by the Food and Drug Administration for therapeutic purposes, and some of these and others have also been radiolabelled for diagnostic and therapeutic purposes. This field is in continuous evolution and this overview highlights the role of radiolabelled antibodies in research and clinical setting.

top of page